BioDelivery Sciences International (BioDelivery Sciences International) Change In Receivables : $-8.7 Mil (TTM As of Dec. 2021)

View and export this data going back to 2002. Start your Free Trial

What is BioDelivery Sciences International Change In Receivables?

BioDelivery Sciences International's change in receivables for the quarter that ended in Dec. 2021 was $0.7 Mil. It means BioDelivery Sciences International's Accounts Receivable declined by $0.7 Mil from Sep. 2021 to Dec. 2021 .

BioDelivery Sciences International's change in receivables for the fiscal year that ended in Dec. 2021 was $-8.7 Mil. It means BioDelivery Sciences International's Accounts Receivable increased by $8.7 Mil from Dec. 2020 to Dec. 2021 .

BioDelivery Sciences International's Accounts Receivable for the quarter that ended in Dec. 2021 was $56.9 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. BioDelivery Sciences International's Days Sales Outstanding for the three months ended in Dec. 2021 was 120.25.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. BioDelivery Sciences International's liquidation value for the three months ended in Dec. 2021 was $32.0 Mil.

BioDelivery Sciences International Change In Receivables Historical Data

The historical data trend for BioDelivery Sciences International's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioDelivery Sciences International Change In Receivables Chart

BioDelivery Sciences International Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Change In Receivables

Get a 7-Day Free Trial

-5.88

-4.64

-25.16

-9.36

-8.72

BioDelivery Sciences International Quarterly Data
	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21
Change In Receivables	Get a 7-Day Free Trial															-4.32	-0.14	-4.58	-4.70	0.71

BioDelivery Sciences International Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $-8.7 Mil.

BioDelivery Sciences International (NAS:BDSI) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

BioDelivery Sciences International's Days Sales Outstanding for the quarter that ended in Dec. 2021 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	56.867	/	43.154	*	91
=	120.25

2. In Ben Graham's calculation of liquidation value, BioDelivery Sciences International's accounts receivable are only considered to be worth 75% of book value:

BioDelivery Sciences International's liquidation value for the quarter that ended in Dec. 2021 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	114.309	-	136.774	+	0.75 * 56.867	+	0.5 * 23.711
=	32.0

BioDelivery Sciences International Change In Receivables Related Terms

Thank you for viewing the detailed overview of BioDelivery Sciences International's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

BioDelivery Sciences International (BioDelivery Sciences International) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » BioDelivery Sciences International Inc (NAS:BDSI) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

4131 ParkLake Avenue, Suite 225, Raleigh, NC, USA, 27612

Website

http://www.bdsi.com

BioDelivery Sciences International Inc is a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic pain. The company is utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA) technology and other drug delivery technologies to develop and commercialize, either on its own or in partnership with third parties, new applications of therapies aimed at addressing important unmet medical needs. Its products include Belbuca and Symproic.

Executives

James Vollins	officer: See Remarks	C/O BIODELIVERY SCIENCES INTERNATIONAL, 4131 PARK LAKE AVE SUITE 225, RALEIGH NC 27607
Mark A Sirgo	director	C/O BIODELIVERY SCIENCES INTERNATIONAL, 801 CORPORATE CENTER DRIVE -SUITE 210, RALEIGH NC 27607
Broadfin Healthcare Master Fund Ltd	director	C/O 20 GENESIS CLOSE, ANSBACHER HOUSE, 2ND FLOOR, PO BOX 1344, GRAND CAYMAN E9 KY1-1108
Kevin Kotler	director	C/O BROADFIN CAPITAL, LLC, 300 PARK AVENUE, 25TH FLOOR, NEW YORK NY 10022
Mary Theresa Coelho	officer: See Remarks	52 SUNRISE PARK ROAD, NEW HAMPTON NY 43017
Jeffrey Allen Bailey	director, officer: Chief Executive Officer	BIODELIVERY SCIENCES INTERNATIONAL, INC., 4131 PARKLAKE AVE., SUITE 225, RALEIGH NC 27612
Todd C Davis	director	11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
W. Mark Watson	director	324 S. HYDE PARK AVENUE, STE 350, TAMPA FL 33606
Peter Greenleaf	director	ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878
Broadfin Capital, Llc	director	300 PARK AVENUE, 25TH FLOOR, NEW YORK NY 10022
Vanila Singh	director	C/O BIODELIVERY SCIENCES INTERNATIONAL, 4131 PARKLAKE AVE., SUITE 225, RALEIGH NC 27612
Scott M. Plesha	officer: See Remarks	1410 SMYTHE ST DANIEL ISLAND SC 29492
Odonnell Francis E Jr	director	BIODELIVERY SCIENCES INTERNATIONAL, INC, 4131 PARKLAKE AVENUE, SUITE #225, RALEIGH NC 27612
Herm Cukier	director, officer: Chief Executive Officer	C/O BIODELIVERY SCIENTES INT., INC. 4131 PARKLAKE AVE, SUITE 225 RALEIGH NC 27612
Thomas B Smith	officer: Chief Medical Officer	BIODELIVERY SCIENCES INTERNATIONAL, INC., 4131 PARKLAKE AVE SUITE 225, RALEIGH NC 27612